<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00516958</url>
  </required_header>
  <id_info>
    <org_study_id>OIS-005</org_study_id>
    <nct_id>NCT00516958</nct_id>
  </id_info>
  <brief_title>Pilot Study of the Safety and Clinical Efficacy of Topical Dermacyn™ Wound Care to Treat Mild Diabetic Foot Infections</brief_title>
  <official_title>An Open Label, Three Arm, Pilot Study of the Safety and Clinical Efficacy of Topical Dermacyn™ Wound Care vs. Oral Levofloxacin vs. Combined Therapy for Mild Diabetic Foot Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oculus Innovative Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oculus Innovative Sciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the rates of clinical success of Topical Dermacyn™ vs. Oral Levofloxacin vs.
      Combined therapy, in subjects with mild diabetic foot infections in non-ischemic ulcers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the rates of clinical success (cure + improvement) of Topical Dermacyn™ vs. Oral Levofloxacin vs. Combined therapy, in patients with mild diabetic foot infections in non ischemic ulcers</measure>
    <time_frame>Visit 3 (Day 10); Visit 4 (Day 24)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the treatment groups with respect to microbiological outcome. Incidence of adverse events and other safety outcomes</measure>
    <time_frame>Visit 2 (Day 3); Visit 3 (Day 10)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Foot Ulcer, Diabetic</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical Dermacyn</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical Dermacyn and levofloxacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical saline and levofloxacin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Dermacyn</intervention_name>
    <description>Topical Dermacyn once a day for 10 Days</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Dermacyn™ Wound Care</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Dermacyn and Levofloxacin</intervention_name>
    <description>Topical Dermacyn once a day and levofloxacin 750 mg PO per day; both for 10 days</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Dermacyn™ Wound Care</other_name>
    <other_name>Levaquin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Saline and Levofloxacin</intervention_name>
    <description>Topical saline once a day and levofloxacin 750 mg PO daily, both for 10 days</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Saline Solution</other_name>
    <other_name>Levoquin®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A patient must meet all of the following inclusion criteria to be enrolled in the
             study:

               1. Males and females &gt; 18 years of age with diabetes mellitus (type 1 or type 2,
                  controlled).

               2. Presence of infected, non-ischemic diabetic foot ulcer that involves skin and
                  deeper soft tissue as stratified by IDSA guidelines and the UTC / 1B.

               3. Foot infections that are anticipated to be cured in 10 days of oral antibiotic
                  therapy.

               4. Foot ulcers located in the plantar, dorsal or malleolar areas.

               5. Ulcers 1- 9 cm2 in size.

               6. An accessible infection site for culture.

               7. ABI by Doppler ≥ 0.8 or TcPO2 ≥ 30 mmHg.

               8. Palpable pulse on the study foot (either dorsalis or posterior tibial artery).

               9. Willing and able to give informed consent.

              10. Willing to comply with the requirements for participation in the study.

        Exclusion Criteria:

        Patients are excluded if they meet any of the following criteria at the time of
        randomization:

          1. Previous antibiotic treatment received for more than 24 hours within 72 hours of
             study.

          2. Necrotizing fasciitis, deep abscesses in the soft tissue, sinus tracts, gas gangrene,
             or infected burns.

          3. Superinfected eczema or other chronic inflammatory skin conditions (i.e., atopic
             dermatitis).

          4. The patient´s ulcer is located on the stump of an amputated extremity.

          5. The patient's ulcer is due to a non-diabetic etiology.

          6. Infections complicated by the presence of prosthetic materials.

          7. Osteomyelitis

          8. Females of childbearing potential who are unable to take adequate contraceptive
             precautions or are breastfeeding.

          9. Known to have liver disease, with total bilirubin &gt; 5 times the Upper Limit of Normal
             (ULN); known to have neutropenia (absolute neutrophil count &lt;500 cells/mm3).

         10. Hypersensitivity to chlorine or quinolones.

         11. Need for any additional concomitant systemic antibacterial agent other than the study
             drug(s).

         12. Concomitant glucocorticoid doses (&gt; 5mg prednisone a day or equivalent).

         13. Adjuvant therapy with hyperbaric oxygen or topical formulations containing growth
             factors, antimicrobials or enzymatic debriders.

         14. A history of diseases of immune function (HIV, chronic granulomatous disease).

         15. Any medical condition that, in the investigator´s opinion, will require dose
             modification of Levofloxacin to less than 750 mg a day.

         16. Has received an investigational agent ≤1 month prior to the baseline evaluation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andres Gutierrez, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Oculus Innovative Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90063-2326</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103-8896</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>34669</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spring Hill</city>
        <state>Florida</state>
        <zip>34609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harrisburgh</city>
        <state>Pennsylvania</state>
        <zip>17112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hazleton</city>
        <state>Pennsylvania</state>
        <zip>18201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>54102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Goretti C, Mazzurco S, Nobili LA, Macchiarini S, Tedeschi A, Palumbo F, Scatena A, Rizzo L, Piaggesi A. Clinical outcomes of wide postsurgical lesions in the infected diabetic foot managed with 2 different local treatment regimes compared using a quasi-experimental study design: a preliminary communication. Int J Low Extrem Wounds. 2007 Mar;6(1):22-7.</citation>
    <PMID>17344198</PMID>
  </reference>
  <reference>
    <citation>Landa-Solis C, González-Espinosa D, Guzmán-Soriano B, Snyder M, Reyes-Terán G, Torres K, Gutierrez AA. Microcyn: a novel super-oxidized water with neutral pH and disinfectant activity. J Hosp Infect. 2005 Dec;61(4):291-9. Epub 2005 Oct 19.</citation>
    <PMID>16242210</PMID>
  </reference>
  <reference>
    <citation>Duc Ql, Breetveld M, Middelkoop E, Scheper RJ, Ulrich MM, Gibbs S. A cytotoxic analysis of antiseptic medication on skin substitutes and autograft. Br J Dermatol. 2007 Jul;157(1):33-40. Epub 2007 Jun 6.</citation>
    <PMID>17553033</PMID>
  </reference>
  <reference>
    <citation>Medina-Tamayo J, Sánchez-Miranda E, Balleza-Tapia H, Ambriz X, Cid ME, González-Espinosa D, Gutiérrez AA, González-Espinosa C. Super-oxidized solution inhibits IgE-antigen-induced degranulation and cytokine release in mast cells. Int Immunopharmacol. 2007 Aug;7(8):1013-24. Epub 2007 Apr 16.</citation>
    <PMID>17570318</PMID>
  </reference>
  <reference>
    <citation>Záhumenský E. [Infections and diabetic foot syndrome in field practice]. Vnitr Lek. 2006 May;52(5):411-6. Review. Czech.</citation>
    <PMID>16771079</PMID>
  </reference>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2007</study_first_submitted>
  <study_first_submitted_qc>August 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2007</study_first_posted>
  <last_update_submitted>January 7, 2008</last_update_submitted>
  <last_update_submitted_qc>January 7, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2008</last_update_posted>
  <responsible_party>
    <name_title>Andres Gutierrez, M.D., Ph.D.</name_title>
    <organization>Oculus Innovative Sciences, Inc.</organization>
  </responsible_party>
  <keyword>diabetic</keyword>
  <keyword>ulcer</keyword>
  <keyword>infection</keyword>
  <keyword>topical</keyword>
  <keyword>wound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Sodium Hypochlorite</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

